HK1116418A1 - Pharmaceutical formulation for increasing solubility of 10- hydroxycamptothecin compounds in non-aqueous polar solvents - Google Patents

Pharmaceutical formulation for increasing solubility of 10- hydroxycamptothecin compounds in non-aqueous polar solvents

Info

Publication number
HK1116418A1
HK1116418A1 HK08106711.7A HK08106711A HK1116418A1 HK 1116418 A1 HK1116418 A1 HK 1116418A1 HK 08106711 A HK08106711 A HK 08106711A HK 1116418 A1 HK1116418 A1 HK 1116418A1
Authority
HK
Hong Kong
Prior art keywords
hydroxycamptothecin
compounds
pharmaceutical formulation
polar solvents
aqueous polar
Prior art date
Application number
HK08106711.7A
Other languages
English (en)
Inventor
Min-Hyo Seo
Hye-Won Kang
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp filed Critical Samyang Corp
Publication of HK1116418A1 publication Critical patent/HK1116418A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK08106711.7A 2004-11-05 2008-06-18 Pharmaceutical formulation for increasing solubility of 10- hydroxycamptothecin compounds in non-aqueous polar solvents HK1116418A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040089876 2004-11-05
PCT/KR2005/003706 WO2006049447A1 (en) 2004-11-05 2005-11-04 Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents

Publications (1)

Publication Number Publication Date
HK1116418A1 true HK1116418A1 (en) 2008-12-24

Family

ID=36319415

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106711.7A HK1116418A1 (en) 2004-11-05 2008-06-18 Pharmaceutical formulation for increasing solubility of 10- hydroxycamptothecin compounds in non-aqueous polar solvents

Country Status (12)

Country Link
US (1) US20070254905A1 (xx)
EP (1) EP1824485B1 (xx)
JP (1) JP4891912B2 (xx)
KR (1) KR100848919B1 (xx)
CN (1) CN101106995B (xx)
AU (1) AU2005301500B2 (xx)
CA (1) CA2584622C (xx)
ES (1) ES2391775T3 (xx)
HK (1) HK1116418A1 (xx)
MX (1) MX2007005293A (xx)
NZ (1) NZ554677A (xx)
WO (1) WO2006049447A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038944A1 (en) * 2006-09-26 2008-04-03 Samyang Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
CN106551910A (zh) * 2015-09-17 2017-04-05 四川赛诺唯新生物技术有限公司 一种含喜树碱衍生物的注射制剂、其注射液、制备和应用
DK3641730T3 (da) 2017-06-22 2021-05-03 Snbioscience Inc Partikel og farmaceutisk sammensætning, der omfatter en uopløselig camptothecinforbindelse med dobbelt kerneskalstruktur og fremgangsmåde til fremstilling heraf
WO2023033990A1 (en) * 2021-09-05 2023-03-09 Chien Du Shieng Formulations with enhanced sn-38 solubility and oral absorption
CN113980029B (zh) * 2021-10-26 2023-05-23 沈阳药科大学 Sn38类甘油三酯前药、脂质制剂及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US5081115A (en) * 1987-10-15 1992-01-14 The Board Of Trustees Of The Leland Stanford Junior University Method to prevent neonatal jaundice with metalloporphyrin compositions
JP2848958B2 (ja) * 1990-09-28 1999-01-20 スミスクライン・ビーチャム・コーポレイション 水溶性カンプトテシン類似体、方法および手段
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
TWI245768B (en) * 2001-02-21 2005-12-21 Yakult Honsha Kk Process for synthesizing camptothecin related compound(s)
CN1798544A (zh) 2003-04-02 2006-07-05 塞拉特药物股份有限公司 喜树碱和氟嘧啶的组合物
WO2005042539A1 (en) * 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CN1875022B (zh) * 2003-10-29 2010-05-26 搜讷斯医药股份有限公司 生育酚修饰的治疗性药物化合物

Also Published As

Publication number Publication date
EP1824485B1 (en) 2012-09-19
EP1824485A4 (en) 2007-11-14
WO2006049447A1 (en) 2006-05-11
US20070254905A1 (en) 2007-11-01
AU2005301500A1 (en) 2006-05-11
ES2391775T3 (es) 2012-11-29
MX2007005293A (es) 2007-07-19
EP1824485A1 (en) 2007-08-29
CN101106995A (zh) 2008-01-16
KR20070074575A (ko) 2007-07-12
CN101106995B (zh) 2011-10-19
CA2584622C (en) 2010-10-26
CA2584622A1 (en) 2006-05-11
JP2008518909A (ja) 2008-06-05
AU2005301500B2 (en) 2011-02-03
KR100848919B1 (ko) 2008-07-29
JP4891912B2 (ja) 2012-03-07
NZ554677A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
IL180630A0 (en) Pyrrole derivatives as pharmaceutical agents
IL220544A (en) History of n - (h1 - indazole - 4 - ram) imidazo [2,1 - a] pyridine - 3 - carboxamide, processes for their preparation and pharmaceutical preparations containing them
IL177424A0 (en) Galenic formulations of organic compounds
IL177120A0 (en) Formulations for poorly soluble drugs
ZA200700352B (en) Pyrrole derivatives as pharmaceutical agents
IL180597A0 (en) Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
SI1863458T2 (sl) Sistem topil za povečanje topnosti farmacevtskih sredstev
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
EP1776112A4 (en) HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
EP2217216A4 (en) FORMULATIONS FOR INCREASED BIOVERABILITY OF ORAL ADMINISTRATIVE POLAR DERIVATIVES
HK1116418A1 (en) Pharmaceutical formulation for increasing solubility of 10- hydroxycamptothecin compounds in non-aqueous polar solvents
PL1809253T3 (pl) Stabilizowana liofilizowana formulacja dla pochodnych cefalosporyny
IL182950A0 (en) Liposomal formulation for oral administration of glutathione (reduced)
HK1113308A1 (en) Pharmaceutical formulations of gallium salts
IL184034A0 (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
PL2040736T3 (pl) Nowa formulacja do zwiększenia biodostępności neurturyny
EP1755682A4 (en) SOLID PHARMACEUTICAL PREPARATION
PL381612A1 (pl) Pirydynowe pochodne alkilooksindoli jako aktywne czynniki 5-HT7
EP2060572A4 (en) PYRAZOLOPYRIDINE DERIVATIVE AND THIS ACTIVE PHOSPHODIESTERASE (PDE) INHIBITOR
ZA200706110B (en) Pharmaceutical formulations of gallium salts
GB2404856B (en) Stable pharmaceutical composition of rabeprazole
ZA200904360B (en) Methods and formulations for improved bioavailability of antiprogestins
IL181838A0 (en) Difluoro-substituted imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2004901107A0 (en) Alkaloid formulation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211104